Palisade Bio Inc. (PALI)
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
📈 **POSITIVE** • Low confidence analysis (30%) • Moderate positive factor • Good growth prospects **Sentiment:** Positive (55%) **Content type:** General